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A paramyxovirus SV5 mutant (rSV5-P/V-CPI) that encodes 6 naturally-occurring P/V gene substitutions is a potent inducer of type I
interferon (IFN) and is restricted for low moi growth, two phenotypes not seen with WT SV5. In this study, we have compared the IFN
sensitivity of WT SV5 and the rSV5-P/V-CPI mutant in tumor cell lines and in cultures of normal primary cells. We have tested the
hypothesis that differences in IFN induction elicited by WT rSV5 and rSV5-P/V-CPI are responsible for differences in low moi growth and
spread. In contrast to WT SV5, low moi infection of A549 lung carcinoma cells with rSV5-P/V-CPI resulted in a plateau of virus
production by 24–48 h pi when secreted IFN levels were between ~100 and 1000 U/ml. Gene microarray and RT-PCR analyses identified
IFN genes and IFN-stimulated genes whose expression were increased by infection of A549 cells with WT and P/V mutant viruses.
Restricted low moi growth and spread of rSV5-P/V-CPI in A549 cells was relieved in the presence of neutralizing antibodies to IFN-h but
not TNF-a. When A549 or MDA-MB-435 breast tumor cells were pretreated with IFN, both WT and P/V mutant viruses showed delayed
spread and ~10-fold reduction in virus yield, but infections were not eliminated. Using normal primary human epithelial cells that have
undergone limited passage in culture, WT rSV5 and rSV5-P/V-CPI displayed high moi growth properties that were similar to that seen in
A549 cells. However, IFN pretreatment of these primary cells as well as normal human lung cells eliminated low moi spread of both mutant
and WT rSV5 infections. Together, these data demonstrate that SV5 growth in normal primary human cells is highly sensitive to IFN
compared to growth in some tumor cell lines, regardless of whether the P/V gene is WT or mutant. These results suggest a model in which
spread of WT SV5 in normal human cells is dependent on the ability of the virus to prevent IFN synthesis. The implications of these results
for the use of recombinant paramyxoviruses as vectors are discussed.
D 2005 Elsevier Inc. All rights reserved.Introduction
The ability of a virus to spread from an initial small
number of infected cells to new cells in a population can be
an important factor in viral pathogenesis, tissue tropism, and
dissemination to new hosts. The type I interferons (IFNs)
are one of the most important antiviral cytokines that can0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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Bethesda, MD 20289, USA.limit virus spread (Biron and Sen, 2001; Stark et al., 1998),
and can be a major determinant of the outcome of a viral
infection (Biron and Sen, 2001; Lyles, 2000). The IFN
response involves two phases: the induction of IFN
synthesis in a primary transcriptional phase and signaling
through the type I IFN signaling pathway to activate a
secondary transcriptional phase (reviewed in Biron and Sen,
2001; Levy, 2002). Synthesis of IFN-h can be induced by
byproducts of virus infection which activate latent tran-
scription factors such as the IFN regulatory factors (IRFs;
Taniguchi et al., 2001) that translocate to the nucleus and
activate the IFN-h promoter. The IFN signaling phase is
initiated when secreted IFN binds to its receptor on the cell05) 131–144
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transcription factors called STAT1 and STAT2 (signal
transducers and activators of transcription) which then
heterodimerize and associate with IRF-9 to form the
transcription factor ISGF3. This transcription factor binds
to IFN-stimulated response elements (ISRE) located in the
promoter region of IFN-inducible genes (reviewed in
Horvath, 2000). Many of the interferon-stimulated gene
(ISG) products have antiviral activity and can contribute to
the inhibition of host and viral protein synthesis, induction
of apoptosis, and clearance of viral infections (reviewed in
Biron and Sen, 2001; Sen, 2000).
Members of the paramyxovirus family of negative strand
RNA viruses employ a diverse range of mechanisms to
circumvent IFN, including blocks in the induction of IFN,
the activation of IFN signaling pathways or both of these
processes (reviewed in Garcia-Sastre, 2001; Goodbourn et
al., 2000; Horvath, 2004). For example, some paramyx-
oviruses such as Newcastle Disease virus and some strains
of Sendai virus (SeV) induce IFN, but efficiently suppress
IFN responses. SeV infection results in a block in IFN
signaling and recent evidence suggests that the SeV C
proteins are involved in STAT1 inactivation (Garcin et al.,
1999; Takeuchi et al., 2001). SV5 and other paramyxovi-
ruses in the rubulavirus genus do not express C proteins, but
utilize the V protein for circumventing IFN. The SV5 V
protein is multi-functional, and has been found to interact
with the DNA damage binding domain 1 (DDB1; Lin et al.,
1998) through interactions that require a unique C-terminal
cysteine-rich region that binds zinc (Paterson et al., 1995).
The SV5 V protein targets STAT1 for degradation by the
proteasome (Didcock et al., 1999b), resulting in a block in
type I and type II IFN signaling. Recently, the SV5 V
protein has also been shown to play a role in blocking the
primary transcription phase of the IFN response, as trans-
location of IRF-3 to the nucleus was blocked following SV5
infection (He et al., 2002). The V protein is able to block
induction of the IFN-h promoter when expressed from DNA
plasmids (Poole et al., 2002). Thus, the SV5 V protein plays
multiple roles in counteracting host IFN responses, being
involved in blocking both IFN induction and signaling
pathways (Andrejeva et al., 2002; Didcock et al., 1999b; He
et al., 2002; Poole et al., 2002).
V and P proteins are produced from the paramyxovirus
P/V gene by co-transcriptional addition of non-template G
residues (Lamb and Kolakofsky, 2001), resulting in a shared
amino-terminal segment (the P/V region) but different C-
terminal regions. The common N-terminal P/V region and
the unique cys-rich C-terminal domain of the rubulavirus V
protein both contribute to counteracting IFN responses
(Chatziandreou et al., 2002; He et al., 2002; Kawano et al.,
2001; Kubota et al., 2001; Wansley and Parks, 2002). For
SV5, a truncated V protein that lacks the C-terminal cys-rich
domain is unable to block the primary IFN induction phase
or the secondary IFN signaling phase when expressed from
a recombinant SV5 (rSV5) or from DNA plasmids (He etal., 2002; Poole et al., 2002). In contrast to the conserved C-
terminal domain, the N-terminal shared region of the SV5 P/
V protein can vary in sequence between independent natural
isolates of SV5 (Chatziandreou et al., 2004), and is also
important for a number of V protein functions. This is most
evident in the case of two naturally occurring SV5 variants,
canine parainfluenza virus (CPI) plus and minus (Baum-
gartner et al., 1991; Chatziandreou et al., 2002). Previous
work has shown that these two naturally occurring isolates
differ in their ability to degrade STAT1 in human cells: CPI+
can degrade STAT1 like WT SV5, while CPI cannot
degrade STAT1 and is highly sensitive to IFN treatment
(Chatziandreou et al., 2002, 2004). The CPI+ and CPI V
proteins differ by three substitutions in the common N-
Terminal P/V region, and transfection experiments have
shown that all three of these amino acid changes contribute
to the contrasting ability of the CPI+ and CPI V proteins
to block IFN signaling (Chatziandreou et al., 2002).
We have previously engineered an rSV5 mutant (rSV5-P/
V-CPI, Wansley and Parks, 2002) to encode the same six
P/V substitutions found in the CPI variant which is
defective in targeting STAT1 degradation (Chatziandreou et
al., 2002). The growth properties of the rSV5-P/V-CPI
mutant were very different from both the parental bona fide
CPI virus and WT rSV5. WT rSV5 blocks IFN signaling
(Didcock et al., 1999b), is a poor inducer of IFN as well as
other cytokines (Didcock et al., 1999a; He et al., 2002;
Young and Parks, 2003), and causes a long-term, non-
cytopathic infection of human cells. Introducing the six CPI-
minus-derived substitutions into the P/V gene converts WT
rSV5 into a mutant that shows: (1) higher-than-WT growth
kinetics at high moi, (2) potent induction of IFN and other
antiviral cytokines, (3) an inability to block IFN signaling,
and (4) a restriction on growth following low moi infection
(Wansley and Parks, 2002; Wansley et al., 2003). In this
study, we have tested the hypothesis that differences in IFN
induction between infections with WT SV5 and rSV5-P/V-
CPI are responsible for differences in low moi growth and
spread.
Paramyxoviruses are generally thought to be highly
resistant to the antiviral effects of IFN (Garcia-Sastre, 2001;
Goodbourn et al., 2000), and SV5 is thought to be
particularly potent in this regard. SV5 is capable of inducing
degradation of STAT1 in tissue culture cells that have
entered an antiviral state (Didcock et al., 1999b), and this
may account for the finding that SV5 growth is slowed but
not blocked in IFN treated cells (Andrejeva et al., 2002;
Didcock et al., 1999a). By contrast, the bona fide CPI
which cannot degrade STAT1, is much more sensitive for
growth in IFN treated cell lines (Chatziandreou et al., 2002).
These findings with tissue culture cell lines have led us to
compare the IFN sensitivity of WT SV5 and our recombi-
nant rSV5-P/V-CPI mutant in tumor cell lines and in
cultures of normal primary cells. Both viruses showed
modest delays in virus growth and spread in IFN-treated
tumor cell lines, but infections were not eliminated. Thus, in
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P/V-CPI harboring the CPI P/V substitutions is rela-
tively resistant to IFN pretreatment in many tissue culture
cell lines. Strikingly, however, both WT and P/V mutant
SV5 were highly sensitive to exogenously-added IFN in
cultures of normal primary cells. Thus, a major factor in the
IFN resistance or sensitivity of our P/V mutant SV5 is
whether virus infections are carried out in tumor cell lines or
in normal primary cells. Our results support a model in
which the ability of SV5 to prevent IFN synthesis is an
important factor influencing spread in normal human cells.Fig. 1. Timecourse of virus growth and IFN induction following low moi
infection with WT rSV5-GFP or rSV5-P/V-CPI. A549 cells were mock
infected or infected with rSV5-GFP or rSV5-P/V-CPI at an moi of 0.05.
Media collected at the indicated times pi were analyzed for virus growth
(panel A) and for IFN levels (panel B) as described in Materials and
methods. Data are representative of three independent experiments.Results
Restricted growth and IFN induction following low moi
infection with the rSV5-P/V-CPI virus
We have previously proposed that restricted low moi
growth of the rSV5-P/V-CPI mutant results from an initial
burst of virus replication which induces secretion of antiviral
cytokines that limit spread to uninfected cells (Wansley and
Parks, 2002). To test this proposal, timecourses of virus yield
and levels of secreted IFN were determined following low
moi infection of A549 cells, a human alveolar carcinoma cell
line (Leiber et al., 1976) that is typically used for para-
myxovirus studies. A WT rSV5 encoding GFP as an
additional transcription unit between HN and L was used
to control for the GFP encoded by the mutant virus, and this
additional gene has been shown previously to have no
detectable affect on rSV5 growth properties (He et al., 1997).
As shown in Fig. 1A, low moi infection with rSV5-GFP
resulted in an initial lag in appearance of progeny virus, but
yields continued to increase out to 72–96 h pi. By contrast,
growth of rSV5-P/V-CPI showed an initial rapid burst of
virus production at 12 h pi that was ~100-fold greater than
rSV5-GFP, but yields quickly plateaued by 36–48 h pi at a
level that was ~2 logs lower than the final yield of WT
rSV5-GFP. A large number of cells remain viable after low
moi infection with rSV5-P/V-CPI (data not shown),
consistent with the hypothesis that restricted virus produc-
tion by the cytopathic rSV5-P/V-CPI virus was due to
restricted spread through the population.
To determine the kinetics and level of secreted IFN,
A549 cells were mock infected or infected at low moi with
WT rSV5-GFP or the rSV5-P/V/CPI mutant. IFN levels in
the media were determined with a VSV-based bioassay. As
shown in Fig. 1B, low moi infection of A549 cells with WT
rSV5-GFP did not result in IFN secretion above that seen
with mock-infected cells, consistent with previous results
showing that WT rSV5 is a poor inducer of IFN (Didcock et
al., 1999a; He et al., 2002). By contrast, low moi infection
with rSV5-P/V-CPI showed a time-dependent appearance
of IFN in the media, starting with ~50 U/ml at 24 h pi, and
peaking at ~750 U/ml by 48 h pi. In other experiments,
maximum levels of secreted IFN were between 1000 and1500 U/ml. A comparison of Figs. 1A and B indicates that
virus growth after low moi infection had plateaued when the
level of IFN in the media was ~100–200 U/ml. These results
are consistent with the proposal that the P/V mutant is
growth restricted in A549 cells due to paracrine/autocrine
action of IFN.
Induction of IFN stimulated genes by infection with the
rSV5-P/V-CPI mutant
Our previous results from transfection assays have shown
that infection of A549 cells with rSV5-P/V-CPI but not
WT rSV5 results in activation of reporter genes under
control of promoters for IFN-h and a prototypic ISRE gene
(Wansley and Parks, 2002; Wansley et al., 2003). To
determine if chromosome-encoded ISG expression was
elevated by rSV5-P/V-CPI infection, gene microarray
analysis was carried out on RNA harvested at 24 h pi from
A549 cells that were mock infected or infected at high moi
with rSV5-P/V-CPI or WT rSV5-GFP. Levels of cellular
gene transcripts were determined using Affymetrix gene
chip analysis as described inMaterials and methods. Tables 1
and 2 list representative results from analysis of the level of
Table 1
Fold change in IFN RNA following infection of A549 cells with rSV5-GFP
or rSV5-P/V-CPI
Gene (accession number) rSV5-GFP
vs. mock
rSV5-P/V-CPI
vs. mock
IFN-b, Interferon beta 1
(NM_002176.1)
b2 +151
IFN-a2, Interferon alpha 2
(M54886.1)
b2 +3.1
IFN-a14, Interferon alpha 14
(NM_002172.1)
b2 +9.2
IFN-a16, Interferon alpha 16
(NM_002173.1)
b2 +10.8
IFN-a1, Interferon alpha 1
(NM_024013.1)
b2 +15.4
IFN-a7, Interferon alpha 7
(NM_021057.1)
b2 +27.7
Table 2
Fold change in ISG RNA levels following infection of A549 cells with
rSV5-GFP or rSV5-P/V-CPI
Gene (accession number) rSV5-GFP
vs. mock
rSV5-P/V-CPI
vs. mock
IFN stimulated genes
A PML, Promyelocytic leukemia
protein (NM_002675.1)
b2 +2.2
PKR, Protein kinase, dsRNA
dependent (NM_002759.1)
b2 +3.3
BAK-1, BCL2-antagonist/killer 1
(NM_001188.1)
b2 +4.1
IRF-2, IFN regulatory factor 2
(NM_002198.1)
b2 +4.6
IRF-1, IFN regulatory factor 1
(NM_002199.2)
b2 +5.5
IFITM1 (9–27), IFN-induced
transmembrane protein 1
(NM_003641.1)
b2 +6.1
ADAR, Adenosine deaminase,
RNA-specific (NM_001111.2)
b2 +6.2
B 6-16, IFN-induced 6–16 protein,
isoform c (NM_022873.1)
b2 +11.5
IRF-7, IFN regulatory factor 7
(NM_004030.1)
b2 +25.8
LMP7, Proteasome subunit LMP7
(U17496.1)
b2 +31.8
ISG15, IFN stimulated protein,
15 kDa (NM_005191.1)
b2 +32.2
IFIT4, IFN-induced with
tetratricopeptide repeats 4
(NM_001549.1)
b2 +61.7
MX1, Myxovirus (influenza)
resistance 1 (NM_002462.1)
b2 +66.4
C OAS-1, 2V,5V oligoadenylate
synthetase 1, (NM_002534.1)
+4.5 +98.5
OAS-3, 2V,5V oligoadenylate
synthetase 3, (NM_006187.1)
+6.5 +56.9
ISG20, IFN-stimulated gene
20 kDa (NM_002201.2)
+10.2 +637
IFIT1, IFN-induced with
tetratricopeptide repeats 4
(NM_001548.1)
+42.4 +915
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(Der et al., 1998; Grandvaux et al., 2002).
As shown in Table 1, IFN RNA levels were not elevated
in cells infected by WT rSV5-GFP above that seen with
mock-infected samples. By contrast, cells infected with
rSV5-P/V-CPI showed IFN-h mRNA levels that were
~150-fold higher than that of mock-infected cells. Likewise,
levels of the analyzed IFN-a genes (IFN-a1, IFN-a2, IFN-
a7, and IFN-a14) were elevated ~3- to 27-fold by rSV5-P/
V-CPI infection. As shown in Table 2, levels of ISG RNA
following infection with rSV5-GFP or the P/V mutant could
be grouped into three categories based on fold increase over
that seen with mock-infected cells. Expression of represen-
tative genes in Group A was increased b10-fold by rSV5-P/
V-CPI infection, and was not increased above background
levels by rSV5-GFP infection. These genes included the
RNA-activated protein kinase R (PKR), 9–27, ADAR and
two members of the IRF family of transcription factors
(IRF-1 and IRF-2). Group B contained representative genes
whose expression was elevated N10-fold over mock samples
following rSV5-P/V-CPI infection, but was not above
background levels after infection with WT rSV5-GFP.
Examples of this group included RNA from the LMP7, 6–
16, IRF-7, ISG15, and MX1 genes. The increased levels of
IRF-7 following rSV5-P/V-CPI infection was consistent
with the increased levels of IFN-a gene transcripts shown in
Table 1, since many of the IFN-a genes are transcriptionally
activated by IRF-7 (Levy, 2002). Group C genes were ISGs
expressed above background levels following infection with
both rSV5 and rSV5-P/V-CPI. These Group C genes
included 2V–5V OligoA Synthetase-1 and -3, ISG20 and
ISG56.
RT-PCR analysis was carried out to confirm increased
expression of prototypic ISGs (Der et al., 1998; Grandvaux
et al., 2002). As shown in Fig. 2, low levels of RT-PCR
products were detected for RNA from the 6–16 gene,
consistent with the microarray group B genes. RNAse
treatment of RNA samples eliminated RT-PCR products
(lane 4). PCR products from the 2V–5V OAS, ISG54 andISG56 genes in rSV5-GFP-infected cells were higher than
mock-infected samples. PCR products from rSV5-P/V-
CPI samples were most abundant for each prototypic
ISGs. These data on ISG transcription are important, since
they support a role for IFN responses in restricted low moi
growth of the P/V mutant (Fig. 1).
Neutralization of secreted IFN-b enhances low moi growth
of the rSV5-P/V-CPI mutant
To directly test the role of secreted IFN on restricted
growth of the P/V mutant, A549 cells infected at low moi
with rSV5-GFP or rSV5-P/V-CPI were cultured with
medium containing a neutralizing antibody against human
IFN-h. As shown in Fig. 3A, nearly all cells in the rSV5-
GFP sample were positive for GFP by 48 h pi, indicating a
rapid spread of the infection through the cell population.
The spread of WT rSV5-GFP was not affected by addition
Fig. 2. Induction of ISG expression following infection with rSV5-GFP and
the rSV5-P/V-CPI mutant. RNA isolated at 24 h pi from A549 cells that
were mock infected (lane 1) or infected at an moi of 25 with rSV5-GFP
(lane 2) or rSV5-P/V-CPI (lane 3) was used in an RT-PCR with primers
specific for GAPDH or the indicated ISGs as described in Materials and
methods. The controls in lane 4 are from samples treated with RNAse prior
to RT-PCR amplification. Normalized levels of PCR products were
analyzed by gel electrophoresis.
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TNF-a antibodies. By contrast, only a fraction of the cells in
the control samples of rSV5-P/V-CPI infected cells were
positive for GFP (Fig. 3A), and this did not increase further
at later time pi (see below). The spread of the rSV5-P/V-
CPI infection through the cell population was greatly
enhanced when IFN-h neutralizing antibodies were included
in the media (Fig. 3A, bottom panel), but not with control
neutralizing antibodies against TNF-a. The low moi yield
from rSV5-P/V-CPI infected cells was also higher in the
presence of anti-IFN-h antibodies (Fig. 3B), but final titers
were still ~1 log lower than that seen with WT rSV5-GFP. It
is noteworthy that the increased number of infected cells in
the presence of INF-h antibodies also led to enhanced
cytopathic effect. Taken together, Figs. 1 and 3 indicate that
infection with rSV5-P/V-CPI activates synthesis of IFN
and this is a major factor in restricted low moi growth of the
mutant.
The above results with anti-IFN antibodies were con-
firmed using Vero cells which lack IFN genes (Emeny and
Morgan, 1979). After low moi infection of Vero cells, the
rSV5-P/V-CPI mutant spread rapidly through the popula-
tion and by 48 h pi, N90% of the cells were expressing GFP
(not shown). This was much more rapid than rSV5-GFP,
since only ~20–25% of the cells were positive for GFP by
48 h pi (not shown). Thus, rSV5-P/V-CPI mutant showsless restriction at low moi for cell–cell spread in the
presence of IFN neutralizing antibodies or in IFN-deficient
Vero cell line.
Growth and spread of WT and P/V mutant SV5 through an
A549 cell population is not eliminated by IFN treatment
The above results on induction of IFN synthesis, ISG
expression and restricted growth (Figs. 1–3) could be
explained by a hypothesis that mutant and WT viruses are
equally sensitive to the paracrine effects of IFN, but only
rSV5-P/V-CPI is growth restricted due to induction of IFN
synthesis by the P/V mutant. An alternative hypothesis is
that the P/V mutant and WT viruses differ in both the
induction and in their sensitivity to the paracrine effects of
IFN.
To compare the growth sensitivity of WT and mutant
viruses to IFN, the kinetics of virus spread through an
infected cell population was determined with or without IFN
pretreatment. A549 cells were treated for 24 h with 1000 IU/
ml IFN before being mock infected or infected at an moi of
0.05 with rSV5-GFP or rSV5-P/V-CPI. As shown in Fig.
4A (IFN panels), the rSV5-GFP infection had spread to
most of the cells in the population by 72 h pi. While some
cells in the rSV5-P/V-CPI-infected sample were positive for
GFP expression and showed cytopathic effects, there were a
large number of cells that did not express GFP (Fig 4A,
IFN panel). Quantitation of the kinetics of low moi spread
of infection (Fig. 4B) showed that both WT rSV5-GFP and
rSV5-P/V-CPI had the largest increase in number of GFP-
positive cells between 24 and 48 h pi. However, while WT
rSV5-GFP continued to spread to infect N95% of the cells
by 72 h pi, the number of GFP-positive cells was never
more than 50% of the population with the rSV5-P/V-CPI
infected sample. Thus, the plateau in low moi rSV5-P/V-
CPI production shown in Fig. 1A, mirrors a restriction in
spread of virus through the cell population (Fig. 4B).
In cells pretreated with IFN, spread of the rSV5-P/V-
CPI mutant through the cell population was inhibited to a
greater extent than spread of WT rSV5-GFP. This is evident
in Fig. 4B (+IFN samples), where pretreatment of cells with
1000 IU/ml IFN delayed spread of WT rSV5-GFP through
the cell population with the largest difference between
treated and untreated samples seen at 48 h pi. However,
~70% of the cells in the population eventually became
positive for GFP-expression by 96 h pi. In contrast, the
spread of rSV5-P/V-CPI was severely limited following
treatment with IFN, and a maximum of only ~10% of the
cells were found to express GFP. Thus, differences in low
moi growth of these two viruses are due to the fact that IFN
is induced by the P/V mutant, as well as enhanced IFN
sensitivity of the P/V mutant virus.
The effect of IFN on virus production was determined in
A549 cells that were pretreated for 24 h with various levels
of IFN and then infected at low moi with rSV5-GFP or
rSV5-P/V-CPI. As shown in Fig. 5 for rSV5-GFP,
Fig. 3. Neutralization of secreted IFN-h enhances low moi growth of the rSV5-P/V-CPI mutant. (A) Anti-IFN-I antibodies enhance the spread of the rSV5-P/
V-CPI infection. A549 cells infected at low moi were incubated with untreated media, or media containing neutralizing antibody specific for IFN-h or TNF-a
(control Ab). (A) Representative result of microscopy for GFP-positive cells at 48 h pi. (B) Media samples were analyzed at the indicated times pi for virus
growth. Data are the average of two independent experiments.
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resulted in a dose-dependent reduction in virus yields at
early times pi (48 h, white bars), but final yields were only
slightly decreased compared to control cells (96 h, stippled
bars). By contrast, virus production from rSV5-P/V-CPI
infected cells reached a plateau by 48 h pi (Fig. 5),
regardless of the level of IFN used for pretreatment. The
effect of IFN pretreatment on rSV5-P/V-CPI growth was
most evident by a reduction in the final yields of ~1 log with
all IFN concentrations tested.
Figs. 4 and 5 illustrate two striking phenotypes. First,
growth of both viruses was not abolished by treatment with
very high levels of IFN, since there was only ~10-fold
difference in final yields between the untreated control and
the sample treated with 5000 IU/ml IFN. Secondly, while
spread of the P/V mutant is limited to ~10% and ~40% of
the population with and without IFN pretreatment, respec-
tively (Fig. 4), these infected cells can produce relatively
large amounts of progeny virus (104 PFU/ml and 105 PFU/
ml with and without IFN pretreatment). These data areconsistent with the proposal that rSV5-P/V-CPI virus
produces higher yields on a per cell basis than that of WT
rSV5-GFP, possibly due to overexpression of viral compo-
nents (Wansley and Parks, 2002, Wansley et al., 2003).
Growth and IFN sensitivity of WT rSV5-GFP and
rSV5-P/V-CPI mutant in MDA-MB-435 cells
To determine if the above results seen with A549 alveolar
carcinoma cells also applies to other tumor cell lines, the
growth and IFN sensitivity of WT rSV5 and rSV5-P/V-
CPI viruses was assayed in the breast tumor cell line
MDA-MB-435. As a first step in this analysis, transfection
experiments were carried out to determine the extent to
which infection of MDA-MB-435 cells with mutant and WT
rSV5-GFP leads to activation of the IFN-h promoter and
stimulation of ISRE promoters.
As shown in Fig. 6A, high moi infection of MDA-MB-
435 cells with rSV5-P/V-CPI but not WT rSV5-GFP
resulted in activation of a luciferase reporter gene under
Fig. 4. Effect of IFN pretreatment on spread of low moi rSV5-GFP or rSV5-P/V-CPI infection through a population of cells. (A) Microscopy of rSV5-GFP
and rSV5-P/V-CPI infected cells following IFN pretreatment. Cells were mock treated or pretreated for 24 h with 1000 IU/ml IFN before mock infection or
infection with rSV5-GFP or rSV5-P/V-CPI at an moi of 0.05. Phase contrast and GFP microscopy pictures were taken at 72 h pi. (B) Quantitation of the
kinetics of virus spread following IFN pretreatment. Cells were pretreated with or without 1000 IU/ml IFN for 24 h before infection with rSV5-GFP or rSV5-P/
V-CPI at an moi of 0.05. At each time point, N200 cells were observed for GFP expression by fluorescence microscopy, and percent GFP-positive cells in the
field were calculated. Data are representative of three independent experiments.
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infected MDA-MB-435 cells confirmed that ~2000 U/ml
IFN was secreted in response to infection with rSV5-P/V-Fig. 5. Effect of IFN pretreatment on multi-step growth of rSV5-GFP and rS
concentrations of IFN before infection with rSV5-GFP or rSV5-P/V-CPI at an m
were determined by plaque assay. Data are the average of three experiments, F SCPI (not shown). Similarly, a plasmid containing the
luciferase gene under control of an ISRE was used to
determine if the IFN signaling pathway was functional inV5-P/V-CPI. A549 cells were pretreated for 24 h with the indicated
oi of 0.05. At the indicated times pi, media were harvested and virus titers
D.
Fig. 6. IFN induction, growth and spread of rSV5-GFP and rSV5-P/V-CPI in MDA-MB-435 tumor cells. (A) Induction of the IFN-h promoter. MDA
MB-435 cells were transiently co-transfected with plasmids encoding the luciferase gene under control of the h-IFN promoter and pSV-hgal. Twenty-fou
hours later, cells were mock infected or infected at high moi with rSV5-GFP or rSV5-P/V-CPI. Cells were lysed at 24 h pi and normalized luciferase
activity was calculated as a fold induction over mock-infected cells as described above. Data are representative of 3 experiments. (B) Induction of ISRE
promoter. MDA-MB-435 cells were co-transfected with an ISRE-luciferase reporter plasmid along with pSV-hgal. Twenty-four hours pi, cells were mock
infected or infected with rSV5-GFP or rSV5-P/V-CPI at high moi. At 16 h pi, cells were incubated for 6 h with (hatched bars) or without (white bars
2000 units of IFN. Normalized luciferase activity was calculated as a fold induction over mock samples. (Panels C and D) Low moi spread and virus
production. Dishes of MDA-MB-435 cells were mock treated or pretreated for 24 h with 1000 IU/ml IFN before infection with rSV5-GFP or rSV5-P/V
CPI at an moi of 0.05. At the indicated times pi, the percentage of GFP-expressing cells (panel C) was determined as described in the legend to Fig. 4
Data are representative of three independent experiments. Virus production (panel D) was determined by plaque assay. Data are the average of two
independent experiments.
E.K. Wansley et al. / Virology 335 (2005) 131–144138SV5-infected MDA-MB-435 cells. As shown in Fig. 6B,
exogenously-added IFN stimulated expression from the
ISRE plasmid ~12-fold in mock-infected cells. Cells
infected with WT rSV5-GFP did not activate ISRE-
luciferase expression after the addition of IFN, consistent
with the ability of WT rSV5 to block IFN signaling
pathways (Didcock et al., 1999b). By contrast, cells
infected with the rSV5-P/V-CPI mutant showed acti-
vation of ISRE-luciferase expression even in the absence
of added IFN, suggesting that the rSV5-P/V-CPI
infected cells secrete IFN which then acts on the IFN
receptor to activate ISRE expression as described
previously (Wansley and Parks, 2002). Taken together,
these results indicate that MDA-MB-435 cells can be
activated to secrete IFN and have intact IFN signaling
pathways similar to that seen with infected A549 cells.
To test the sensitivity of WT and P/V mutant SV5 in
MDA-MB-435 cells, dishes of cells were pretreated with or
without 1000 U/ml IFN for 24 h prior to infection at low-
r
)
-
.moi with WT rSV5-GFP or the rSV5-P/V-CPI mutant. As
shown in Fig. 6C, the rSV5-P/C-CPI mutant spread
through the population of control-treated cells faster than
WT rSV5-GFP, with the greatest difference in the percent-
age of GFP-positive cells in these infected cultures being
seen at 36 h pi (hatched bars, Fig. 6C). Likewise, virus
production from control-treated MDA-MB-435 cells (open
symbols, Fig. 6D) was slightly faster for rSV5-P/V-CPI at
early times pi, but final yields were ~10-fold lower than that
of WT SV5-GFP. While the mechanism is presently
unclear, our data indicate that the P/V mutant shows less
of a growth restriction in MDA-MB-435 cells compared to
A549 cells, and spreads efficiently through the population
of cells.
In IFN-pretreated MDA-MB-435 cells, both WT and
mutant viruses showed an initial lag in the number of GFP-
positive cells (Fig. 6C). While the rSV5-GFP infection in
IFN-pretreated cells eventually spread to 100% of the
population, the P/V mutant did not spread to more than
Fig. 7. Growth properties of WT rSV5-GFP and rSV5-P/V-CPI in primary
human epithelial cells. (A) Microscopy of primary prostate epithelial cells
infected with rSV5-GFP and rSV5-P/V-CPI. Primary WFU224PZ cells
were mock infected or infected with rSV5-GFP or rSV5-P/V-CPI at an
moi of 20 and viewed by microscopy at 24 h pi. (B) Western blot for STAT1
in rSV5-GFP and rSV5-P/V-CPI infected cells. WFU92PZ primary
human prostate cells were mock infected or infected at an moi of 20, and
equal amounts of protein were analyzed at 24 h pi by Western blot for
STAT1, SV5 or V protein. *, a cross-reactive host cell protein which serves
as a gel-loading control. (C) Single step growth. Three strains of primary
human prostate epithelial cells were infected at an moi of 20 with rSV5-
GFP or rSV5-P/V-CPI, and virus titers at 24 h pi were determined by
plaque assay.
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and WT SV5-GFP were ~100- to 1000-fold lower than
control treated samples up to 48 h pi. (compare open and
closed symbols, Fig. 6D). While the restriction of low moi
growth of the P/V mutant differs between A549 and MDA-
MB-435 cells, the most important conclusions from these
data are that IFN pre-treatment of MDA-MB-435 cells
delays but does not eliminate the growth of both WT and
P/V mutant viruses, similar to the results seen with A549
cells.Growth of WT rSV5-GFP and rSV5-P/V-CPI virus in
primary human epithelial cells
The recent findings that many tumor cell lines have
defects in IFN-activated antiviral pathways (e.g., Stojdl et
al., 2000; Wong et al., 1997) raised the hypothesis that
growth of WT and P/V mutant SV5 would be more sensitive
to IFN pre-treatment in the case of normal human cells. To
test this hypothesis, we determined virus growth properties
in four strains of normal primary human prostate epithelial
cells that were isolated from patient prostectomies with only
minimal passage.
As an initial step, we determined SV5 growth properties
in the primary cells following high moi infection. As seen in
Fig. 7A, the primary epithelial cells were efficiently infected
with both rSV5-GFP and rSV5-P/V-CPI viruses, as
evident by all of the cells in the population expressed
GFP by 24 h pi. The primary epithelial cells showed higher-
than-WT levels of GFP following rSV5-P/V-CPI infection
(Fig. 7A) and this overexpression phenotype was confirmed
by Western blotting for the P and V proteins (Fig. 7B). In
single step growth assays with three strains of primary cells,
rSV5-P/V-CPI grew to titers that were ~1 log higher than
rSV5-GFP (Fig. 7C). The elevated expression of viral
proteins and virus yield with rSV5-P/V-CPI are consistent
with previous results in tumor cell lines (Wansley and Parks,
2002).
Cellular STAT1 protein is targeted for degradation
following infection of tissue culture cell lines with WT
rSV5 (Didcock et al., 1999b) but with not the rSV5-P/V-
CPI mutant (Wansley and Parks, 2002). As shown in Fig.
7B, analysis of lysates from the infected primary epithelial
cells showed that STAT1 levels were decreased with WT
rSV5-GFP but not with rSV5-P/V-CPI. Infection with the
rSV5-P/V-CPI mutant but not WT rSV5-GFP resulted in
the secretion of IFN (not shown), with levels being ~50-fold
lower than that reported previously for A549 cells (Wansley
and Parks, 2002). Thus, the phenotypes of high moi A549
infections described previously for WT and P/V mutant
viruses are reproduced in normal primary human cells.
The effect of IFN pretreatment on low moi spread of WT
and P/V mutant viruses in primary epithelial cells was
determined as described above for the tumor cell lines.
Typical results of GFP expression at 48 h pi of strain
WFU92PZ cells and a quantitation of virus spread are
shown in Fig. 8. WT rSV5-GFP spread efficiently through
the cell population in the absence of added IFN such that
nearly all of the cells were expressing GFP by 72 h pi.,
while spread of the rSV5-P/V-CPI infection was restricted
to less than 40% of the cells. However, a striking difference
between primary epithelial cells and the A549 and MDA-
MB-435 cell lines was seen in the sensitivity of both WT
and mutant viruses to IFN pretreatment: following IFN
pretreatment, both viruses were severely restricted in spread
through the population (Fig. 8B) and in virus yield (b100
PFU/ml by 72 h pi).
Fig. 8. Low moi growth of both WT rSV5-GFP and the rSV5-P/V-CPI mutant in primary human epithelial cells is highly sensitive to pretreatment with IFN.
WFU92PZ primary human prostate epithelial cells were treated with or without 1000 IU/ml IFN for 24 h before infection at an moi of 0.05 with rSV5-GFP or
rSV5-P/V-CPI. Panel A shows representative results at 48 h pi using WFU92PZ. Panel B is a representative result of the percentage of WFU224PZ cells
expressing GFP determined at 24, 48, and 72 h pi as described in the legend to Fig. 4.
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primary prostate epithelial cells versus A549 cells could
reflect differences between normal primary cells and tumor
cell lines. Alternatively, these differences could reflect
differences between prostate and lung cells. To distinguish
between these possibilities, the IFN sensitivity of WT and P/
V mutant viruses was determined in MRC-9 normal humanFig. 9. Low moi growth of both WT rSV5-GFP and the rSV5-P/V-CPI
mutant in normal human lung cells is highly sensitive to pretreatment with
IFN. Normal MRC-9 human lung cells were treated with or without 1000
IU/ml IFN for 24 h before infection at an moi of 0.05 with rSV5-GFP or
rSV5-P/V-CPI, and the percentage of cells expressing GFP determined at
the indicated times pi as described in the legend to Fig. 4.lung fibroblast cells. As shown in Fig. 9, WT rSV5-GFP
efficiently spread through the population of control-treated
MRC-9 cells, while spread of the P/V mutant quickly
reached a plateau. Most importantly, there were no GFP-
expressing cells detected in cultures of IFN-pretreated
MRC-9 cells, indicating that both WT and rSV5-P/V-CPI
infections were efficiently blocked (Fig. 9).Discussion
Paramyxoviruses have active mechanisms to counteract
IFN responses, and are generally thought to be highly
resistant to IFN (Garcia-Sastre, 2001; Goodbourn et al.,
2000). This is supported by studies on low moi growth of
WT rSV5, which causes long-term persistent and productive
infections in tissue culture cell lines (Chatziandreou et al.,
2002; Choppin, 1964; He et al., 2002; Wansley and Parks,
2002). By contrast, our rSV5-P/V-CPI mutant displays an
unusual low moi growth phenotype which includes an initial
higher-than-WT burst in growth, but virus growth and
spread quickly reaches a low level plateau. Since rSV5-P/V-
CPI is a potent inducer of antiviral cytokines (Wansley
and Parks, 2002; Young and Parks, 2003), one of the goals
of this study was to define the role of IFN in the differential
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CPI mutant. Our results support four conclusions: (1)
secreted IFN is a major contributing factor in limited growth
and spread of the P/V mutant, (2) rSV5-P/V-CPI infection
leads to transcription of bona fide IFN genes and a number
of prototypic ISGs, confirming previous results from trans-
fection studies, (3) WT rSV5 infection also activates
transcription of a subset of ISGs to lower levels, and (4)
infections with both WT and P/V mutant viruses show
delayed growth in IFN-treated tumor cell lines, but are
virtually eliminated in cultures of IFN-treated normal
primary human cells.
It is important to emphasize that our rSV5-P/V-CPI
mutant differs from the bona fide CPI virus which has
been characterized by Chatziandreou et al. (2002). The
rSV5-P/V-CPI virus harbors six amino acid substitutions
in the common P/V region from the bona fide CPI virus
with the remaining viral genes being derived from WT rSV5
and an additional GFP gene inserted between HN and L
(Wansley and Parks, 2002). Thus, direct comparisons on the
IFN sensitivity and growth properties of the rSV5-P/V-
CPI chimera and bona fide CPI virus have not been
carried out. Our work with the genetically defined rSV5-P/
V-CPI recombinant addresses the IFN sensitivity of an
rSV5 mutant which has gained the phenotypes of potent
IFN induction as well as a defect in targeting STAT1 for
degradation.
Previous work with cells engineered to express the SV5
V protein has led to the suggestion that the ability of SV5 to
circumvent the IFN response is not absolute (Young et al.,
2003). Here, we provide direct evidence that infection with
WT rSV5 results in above-background levels of mRNA for
a select few ISGs, including 2V,5V-OAS, ISG54 and ISG56.
Thus, despite inhibiting IRF-3 nuclear translocation (He et
al., 2002), efficiently blocking induction of the IFN-h
promoter, and targeting of STAT1 for degradation (Young et
al., 2000), there are a select few ISGs that apparently escape
these blocks on IFN responses that are imposed by SV5
infection. The fact that low moi infection of human cells
with WT rSV5 efficiently spreads to yield a productive,
noncytopathic infection of the entire population suggests
that the expression of these select few ISGs is either too low
to impact low moi growth or that SV5 is inherently resistant
to these particular antiviral gene products as described for
RSV (e.g., Atreya and Kulkarni, 1999). The increased
expression of ISG56 by WT rSV5-GFP infection is
particularly noteworthy, since this cellular stress-induced
protein has been shown to inhibit cap-dependent translation
by binding to initiation factor eIF3 (Hui et al., 2003). Low
level expression of ISG56 in WT rSV5-GFP-infected cells
could represent a delayed antiviral response as described for
other RNA viruses (e.g., Fredericksen et al., 2004; TenOver
et al., 2002) or leakiness in the block to antiviral responses
induced by WT rSV5 (Young et al., 2003). Randall et al.
have shown that the rate of viral protein synthesis is reduced
significantly at late times pi with WT rSV5 (e.g., Young etal., 2001), and ISG56 expression or similar host cell
antiviral responses may play a role in this phenotype
(Andrejeva et al., 2002; Chatziandreou et al., 2002).
Our gene array and RT-PCR studies have shown that
infection with the rSV5-P/V-CPI mutant results in
increased levels of IFN-h and IFN-a gene products,
consistent with our previous assays using a reporter gene
linked to the IFN-h promoter and with bioassays for
secreted IFN (Wansley and Parks, 2002). Since rSV5-P/V-
CPI is a potent inducer of a number of cytokines (Young
and Parks, 2003), the role of secreted IFN versus other
cytokines such as TNF-a in restricting low moi growth of
the P/V mutant was not clear from previous studies.
However, while low moi spread of the rSV5-P/V-CPI
infection in A549 cells was greatly enhanced in the pre-
sence of IFN-h neutralizing antibodies, virus titers were still
less than that seen with WT rSV5. We propose that when
low moi growth of the cytopathic rSV5-P/V-CPI mutant is
no longer restrained by the paracrine action of IFN sec-
retion/signaling, cell killing becomes a factor that accounts
for this ~1 log difference compared to the noncytopathic
WT rSV5.
The rSV5-P/V-CPI mutant differs from WT rSV5 by
being self-limiting during low moi spread through a cell
population due at least in part to IFN secretion (Fig. 3).
Using IFN pretreatment of A549 cells, we have shown that
the P/V mutant is also more sensitive than WT rSV5 to the
paracrine effects of IFN. This was evident by the finding
that IFN pretreatment of A549 cells results in a delay in low
moi growth and spread of both WT and mutant viruses, but
the rSV5-P/V-CPI virus showed lower spread that was
limited to only ~10% of the cells. Pretreatment of cells with
IFN primes antiviral responses for a more rapid and more
robust activation (reviewed in Biron and Sen, 2001; Levy,
2002). Thus, a secondary signal which is recognized by the
IFN-primed cells and is provided by rSV5-P/V-CPI but
not WT rSV5 infections may account for this difference in
the ability of these two viruses to spread through an IFN-
pretreated population.
There is experimental evidence that SV5 can naturally
infect humans (reviewed in Chatziandreou et al., 2004), and
it has been proposed that the ability of paramyxoviruses to
establish persistent infections is linked to the ability to block
IFN signaling (Andrejeva et al., 2002; Chatziandreou et al.,
2002). These findings prompted us to compare the growth
of WT rSV5 and a genetically defined SV5 P/V mutant in
primary human epithelial cells that have undergone limited
growth in culture. The high moi growth properties of mutant
and WT rSV5 in the primary epithelial cells were very
similar to those shown previously for tumor cell lines
(Wansley and Parks, 2002). However, both WT rSV5 and
the P/V mutant showed a very different IFN sensitivity
phenotype in assays for low moi growth in primary human
epithelial cells compared to A549 cells, and cell–cell spread
and growth of both mutant and WT rSV5 were virtually
eliminated by IFN pretreatment. The ability of a host cell to
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IFN, as well as the ability of a virus to block antiviral
responses are thought to be major determinants of suscept-
ibility to infection, virus spread, and pathogenesis (reviewed
in Garcia-Sastre, 2001; Lyles, 2000). Our findings that both
WT and P/V mutant SV5 are highly restricted for growth in
IFN-treated normal human lung cell lines (Fig. 9) and
primary prostate epithelial cells (Fig. 8) suggest that these
differences in IFN sensitivity are not due to tissue type (e.g.,
lung versus prostate cells), but rather are due to features of
established tumor cell lines (e.g., A549 and MDA-MB-435
cells) versus primary cells with minimal cell passage. This
difference between tumor cell lines and normal cells could
reflect a more uniform response of a normal cell population
to IFN treatment. Alternatively, SV5 growth may be more
sensitive to the level, overall number or combination of
antiviral ISGs that are activated in IFN-treated normal cells
versus conventional tumor cell culture lines. Work is in
progress to identify ISG products differentially expressed in
normal versus tumor cells that may act to restrict SV5
growth.
Our work has implications for natural SV5 infections.
Available data support the proposal that SV5 naturally
infects humans (reviewed recently in Chatziandreou et al.,
2004), and presumably this would involve a stage of growth
and spread in normal cells of the respiratory tract. WT rSV5
is a poor inducer of IFN secretion in tissue culture cells
(Didcock et al., 1999a; He et al., 2002), and this also holds
true for the primary epithelial cells and normal lung cells
evaluated in this study (not shown). We propose that the
ability of SV5 to prevent activation and secretion of IFN to
neighboring cells is an important phenotype that might
allow efficient low moi spread of WT rSV5 through a
population of normal cells (e.g., respiratory tract). In vivo,
IFN can be derived from a number of sources other than the
infected cell itself, including dendritic cells, NK cells, and
other lymphocytes (Biron and Sen, 2001; Levy, 2002);
however, IFN secretion requires that immune cells be
activated by infection or exposure to microbial products.
Thus, we propose that the ability to avoid induction of IFN
secretion is a critical factor for maintaining spread of an
SV5 infection in vivo.
Many tumor cell lines have defects in their IFN signaling
pathways, and are not sensitive to the antiproliferative
effects of IFN (e.g., Stojdl et al., 2000; Wong et al., 1997).
Recently, this phenotype has been exploited to develop
novel approaches for improved tumor-selectivity of onco-
lytic viruses based on their IFN sensitivity (e.g., Ahmed et
al., 2004; Muster et al., 2004; Stojdl et al., 2000). For
example, VSV mutants which cannot block IFN responses
have been shown to replicate in and kill tumor cells that
contain defects in their IFN pathways, but remain self-
attenuated for growth in normal cells that have intact IFN
pathways (Stojdl et al., 2000). Our results presented here are
consistent with this proposal, since the cytopathic rSV5-P/
V-CPI mutant induces IFN secretion, efficiently spreadsthrough a population of cells that are IFN deficient (e.g.,
Vero), does not require IFN signaling for cell killing, and is
highly restricted by IFN for growth in normal cells. Thus,
our cytopathic rSV5 P/V mutant holds promise as an
additional oncolytic RNA virus that could show higher
tumor selectivity and safety by replicating and killing IFN-
deficient tumor cells while being highly sensitive to the IFN
antiviral effects in normal cells (Stojdl et al., 2000).
Analyzing the cellular pathways that are differentially
affected by SV5 viruses that do or do not induce IFN
responses in primary versus transformed cells will shed light
on mechanisms to improve antiviral therapies or develop
more selective therapy vectors.Materials and methods
Cells, viruses, growth analysis, and reporter gene assays
Cultures of A549 and MDA-MB-435 were grown in
DMEM containing 10% fetal bovine serum (FBS). Four
strains of normal primary human prostatic epithelial cells
(WFU62PZ, WFU92PZ, WFU96PZ, and WFU224PZ)
isolated from prostatectomy specimens at Wake Forest
University School of Medicine were grown as detailed
previously (Ahmed et al., 2004; Barreto et al., 2000) in
medium MCDB 105 supplemented with growth factors and
hormones as described (Peehl, 1992; Peehl et al., 1988). The
benign pathology of the specimen adjacent to the regions
used for tissue culture was verified by techniques described
previously (Barclay et al., 2005).
An rSV5 expressing GFP (He et al., 1997) was recovered
as described previously (Parks et al., 2001) from cDNA
plasmid kindly provided by Robert Lamb and Biao He
(Northwestern University). This virus has growth properties
indistinguishable from WT rSV5 lacking the GFP gene (He
et al., 1997). The recovery and growth of rSV5-P/V-CPI
has been described (Wansley and Parks, 2002). The Orsay
strain of VSV was a kind gift of D. Lyles.
To assay virus growth, ~106 cells in 3.5-cm-diameter
dishes were infected at an moi of 0.05 (multi-step growth) or
50 (single-step growth) for 1 h, washed and covered with 1
ml of DMEM containing 2% FBS. Following infection,
medium samples were removed at various times, clarified
by centrifugation (1 min, 14,000  g), adjusted to 0.75%
bovine serum albumin (BSA), and stored frozen for
determination of titer by plaque assay. SV5 plaque assays
were performed on CV-1 cells by using an overlay
containing 1% agar with DMEM, 2% FBS, and 10 mM
HEPES (pH 7.2). Cells were fixed at 4 days pi with 3.7%
formaldehyde, and plaques were visualized after staining
with 0.1% crystal violet.
In some experiments, cells were treated overnight (12–
16 h) with DMEM containing 2% FBS and universal type I
interferon (PBL) at the concentrations indicated in the
figure legends. Levels of secreted IFN were determined by
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and Parks, 2002). Induction of the IFN-h promoter and
activation of the ISRE promoter following SV5 infection
were carried out as detailed previously (Wansley and Parks,
2002).
Fluorescence microscopy
Dishes of cells were mock infected or infected with
rSV5-GFP or rSV5-P/V-CPI at low (0.05) or high (50)
moi. At each time pi, media were removed from cell
monolayers, and replaced with PBS before analyzed by
microscopy using a Nikon Eclipse fluorescence microscope
and a 20 lens. In assays for spread of the virus infection,
the percent GFP-positive cells was calculated by examining
random fields of cells and counting the number of GFP-
positive cells as a percent of total cells in the field. For each
sample, N200 cells were counted. Images were captured
using a QImaging digital camera and processed using
QCapture software. Exposure times were manually set to
be constant between samples. Neutralizing antibodies
specific for IFN-h (Chemicon) or TNF-a (Biosource) were
used at a final concentration of 104 neutralizing units/ml.
Western blotting, apoptosis assays, and gene expression
analysis
For Western blot analysis, cells that had been previously
infected with rSV5-GFP or rSV5-P/V-CPI were lysed in
1% SDS. Equivalent amounts of protein were analyzed by
Western blotting as described previously (Parks et al., 2002)
using rabbit polyclonal antisera to the SV5 P protein or the
cellular STAT1 protein (clone 554, Santa Cruz Biotechnol-
ogy), or a mouse monoclonal antibody to the SV5 V protein
(clone 11; Paterson et al., 1995) followed by HRP-
conjugated secondary antibodies and ECL. Annexin stain-
ing was carried out as described previously (Wansley et al.,
2003).
For microarray analysis, dishes of A549 cells were mock
infected or infected with rSV5-GFP or rSV5-P/V-CPI at
an moi of 20. Total RNA was isolated at 24 h pi using
Trizol reagent, treated with RNAse-free DNAse and ethanol
precipitated. First strand cDNA synthesis using an oligo-dT
primer and subsequent microarray analysis was carried out
using the Microarray Core Facility of the Wake Forest
University Comprehensive Cancer Center using the
HGU133A chip which contains 14,500 characterized
human genes. Data were analyzed using the Affymetrix
Microarray Software version 5 (MASv5) and Affymetrix
Data Mining Tool software. Results shown are representa-
tive of two (rSV5-P/V-CPI) or three (WT rSV5) inde-
pendent array experiments. Genes upregulated at least 2-
fold greater than the mock-infected sample were considered
significant.
To confirm induction of prototypic RNA transcripts, total
RNA was harvested from cell samples using Trizol reagentand treated with RNAse-free DNAase before phenol
extraction and ethanol precipitation. Reverse transcriptase
PCR (RT-PCR) was performed using MMLV reverse
transcriptase (Invitrogen) and an Oligo dT primer. cDNA
products were amplified using Taq polymerase (Promega)
along with primers specific for GAPDH, 2V–5VOAS, ISG54,
ISG56, and 6–16 as described previously (Nusinzon and
Horvath, 2003). Normalized samples were analyzed by
polyacrylamide gel electrophoresis.Acknowledgments
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